NCT03695081

Patient Pathway Pharmacist - Optimal Drug-related Care

Completed NA Last updated 29 June 2023

What this trial tests

NA trial testing Patient Pathway Pharmacist intervention in Hip Fractures in 60 participants. Completed in 28 June 2023.

Timeline

3 September 2018

Primary endpoint
15 June 2019

28 June 2023

Quick facts

Lead sponsor	Sykehuset i Vestfold HF
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	60
Start date	3 September 2018
Primary completion	15 June 2019
Estimated completion	28 June 2023
Sites	1 location across Norway

Drugs / interventions tested

• Patient Pathway Pharmacist intervention

Conditions studied

• Hip Fractures — all drugs for Hip Fractures →
• Aging — all drugs for Aging →
• Patient Fall — all drugs for Patient Fall →

Sponsor

Sykehuset i Vestfold HF — full company profile →

Who can join

18 and older, any sex, with Hip Fractures or Aging. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Medication errors represent the most common cause of patient injury and one of the most frequently reported health related deviation in Norway. The addition of a dedicated clinical pharmacist throughout the hip fracture patient pathway (patient pathway pharmacist) is believed to improve patient safety and ensure optimal drug-related patient care. The pharmacist will perform medication reconciliation at admission to hospital, medication review after surgery and assist physicians with discharge summary. Six weeks after discharge the patient pathway pharmacist will perform a second drug reconciliation and medication review. This study will assess the pharmacists' place and specific tasks in the patient pathway, describe areas where the pharmacist contribute to increased quality of care and assess the benefits and/or disadvantages experienced with introducing a patient pathway pharmacist. The estimated number of patients included is 60. Current practice will be determined by investigating the last 50 patients' medical record and a questionnaire to health care professionals involved in treatment of hip fracture patients. Data from medication reconciliation and drug review will be collected and compared to current practice. After the inclusion period, focus group surveys and/or semi-structured interviews will be executed to describe the perceived improvement in the quality of care. Primary endpoints are: 1) Medication reconciliation score at admission 2) Number of inappropriate drugs for elderly 3) Discharge summary score 4) Discharge summaries following procedure. Secondary endpoints are readmissions and mortality after 30 and 90 days. Qualitative endpoints: 1) Health care professionals experience of current drug-related practice 2) Experienced advantages and disadvantages of a patient pathway pharmacist.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Medication review in hospitalised patients to reduce morbidity and mortality.
   Bülow C, Clausen SS, Lundh A, Christensen M. · · 2023 · cited 37× · PMID 36688482 · DOI 10.1002/14651858.cd008986.pub4
2. Clinical pharmacist intervention to improve medication safety for hip fracture patients through secondary and primary care settings: a nonrandomised controlled trial.
   Henriksen BT, Krogseth M, Andersen RD, Davies MN, et al · · 2023 · cited 10× · PMID 37312222 · DOI 10.1186/s13018-023-03906-2